|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Radiation therapy for portal venous invasion by hepatocellular carcinoma显示文摘AIM: To clarify the efficacy and safety of three-dimensional conformal radiotherapy (3-D CRT) for this disease and to specify patient subgroups suitable for this treatment.METHODS: Fifty-two patients with HCC received PVI-targeted radiation therapy from January 1995 through December 2003. Portal venous invasion (PVI) was found in the second or lower order branches of the portal vein in 6 patients, in the first branch in 24 patients and in the main trunk in 22 patients. Child classifications of liver function before radiation therapy were A, B, and C for 19, 24 and 2 patients, respectively. All patients received three-dimensional conformal radiotherapy with a total dose ranging from 39 to 60 Gy (57.0 Gy in average).RESULTS: Overall survival rates at 1, 2, 3, 4, and 5 years were 45.1%, 25.3%, 15.2%, 10.1%, and 5.1%, respectively. Univariate analysis revealed that Child status, the number of tumor foci, tumor type,transcatheter arterial embolization (TAE) after radiation therapy were statistically significant prognostic factors.Multivariate analysis showed that the number of tumor foci and TAE after radiation therapy were statistically significant.CONCLUSION: The results of this study strongly suggest the efficacy of 3-D CRT as treatment for PVI in HCC. 3-D CRT is recommended in combination with postradiation TAE for PVI of HCC with 5 tumor foci or less in the liver and with Child A liver function. | Keiichi Nakagawa Hideomi Yamashita Kenshiro Shiraishi Naoki Nakamura Masao Tago Hiroshi Igaki Yoshio Hosoi Shuichiro Shiina Masao Omata Masatoshi Makuuchi Kuni Ohtomo | 2005 | World Journal of Gastroenterology2005，11，46： | 14 |
| 2 | Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy显示文摘Antiplatelet therapy is the standard of care for the secondary prevention of acute coronary syndrome and ischemic stroke, especially after coronary intervention. However, this therapy is associated with bleeding complications such as gastrointestinal bleeding, which is one of the most common life-threatening complications. Early endoscopy is recommended for most patients with acute upper gastrointestinal bleeding. After successful endoscopic hemostasis, immediate resumption of antiplatelet therapy with proton-pump inhibitors(PPIs) is recommended to prevent further ischemic events. PPI prophylaxis during antiplatelet therapy reduces the risk of upper gastrointestinal bleeding. The potential negative metabolic interaction between PPIs and clopidogrel is still unclear. | Hiroshi Yasuda Yasumasa Matsuo Yoshinori Sato Sun-ichiro Ozawa Shinya Ishigooka Masaki Yamashita Hiroyuki Yamamoto Fumio Itoh | 2015 | World Journal of Critical Care Medicine2015，4，1： | 13 |
| 3 | An updated review of gastric cancer in the next-generation sequencing era:Insights from bench to bedside and vice versa显示文摘Gastric cancer(GC)is one of the most common malignancies and remains the second leading cause of cancer-related death worldwide.There is an increasing understanding of the roles that genetic and epigenetic alterations play in GCs.Recent studies using nextgeneration sequencing(NGS)have revealed a number of potential cancer-driving genes in GC.Whole-exome sequencing of GC has identified recurrent somatic mutations in the chromatin remodeling gene ARID1A and alterations in the cell adhesion gene FAT4,a member of the cadherin gene family.Mutations in chromatin remodeling genes(ARID1A,MLL3 and MLL)have been found in 47%of GCs.Whole-genome sequencing and whole-transcriptome sequencing analyses have also discovered novel alterations in GC.Recent studies of cancer epigenetics have revealed widespread alterations in genes involved in the epigenetic machinery,such as DNA methylation,histone modifications,nucleosome positioning,noncoding RNAs and microRNAs.Recent advances in molecular research on GC have resulted in the introduction of new diagnostic and therapeutic strategies into clinical settings.The antihuman epidermal growth receptor 2(HER2)antibody trastuzumab has led to an era of personalized therapy in GC.In addition,ramucirumab,a monoclonal antibody targeting vascular endothelial growth factor receptor(VEGFR)-2,is the first biological treatment that showed survival benefits as a single-agent therapy in patients with advanced GC who progressed after firstline chemotherapy.Using NGS to systematically identify gene alterations in GC is a promising approach with remarkable potential for investigating the pathogenesis of GC and identifying novel therapeutic targets,as well as useful biomarkers.In this review,we will summarize the recent advances in the understanding of the molecular pathogenesis of GC,focusing on the potential use of these genetic and epigenetic alterations as diagnostic biomarkers and novel therapeutic targets. | Hiroyuki Yamamoto Yoshiyuki Watanabe Tadateru Maehata Ryo Morita Yoshihito Yoshida Ritsuko Oikawa Shinya Ishigooka Shun-ichiro Ozawa Yasumasa Matsuo Kosuke Hosoya Masaki Yamashita Hiroaki Taniguchi Katsuhiko Nosho Hiromu Suzuki Hiroshi Yasuda Yasuhisa Shinomura Fumio Itoh | 2014 | World Journal of Gastroenterology2014，20，14： | 12 |
| 4 | Comparison of PPIs and H_2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia显示文摘AIM:To compare efficacy of proton pump inhibitors(PPIs)with H2-receptor antagonists(H2RAs)plus prokinetics(Proks)for dysmotility-like symptoms in functional dyspepsia(FD).METHODS:Subjects were randomized to receive openlabel treatment with either rabeprazole 10 mg od(n= 57)or famotidine 10 mg bid plus mosapride 5 mg tid(n=57)for 4 wk.The primary efficacy endpoint was change(%)from baseline in total dysmotility-like dyspepsia symptom score.The secondary efficacy endpoint was patient satisfaction with treatment.RESULTS:The improvement in dysmotility-like dyspep-sia symptom score on day 28 was significantly greater in the rabeprazole group(22.5%±29.2%of baseline) than the famotidine+mosapride group(53.2%± 58.6%of baseline,P<0.0001).The superior benefit of rabeprazole treatment after 28 d was consistent regardless of Helicobacter pylori status.Significantly more subjects in the rabeprazole group were satisfied or very satisfied with treatment on day 28 than in the famotidine+mosapride group(87.7%vs 59.6%,P= 0.0012).Rabeprazole therapy was the only significant predictor of treatment response(P<0.0001),defined as a total symptom score improvement≥50%.CONCLUSION:PPI monotherapy improves dysmotility-like symptoms significantly better than H2RAs plus Proks,and should be the treatment of first choice for Japanese FD. | Masahiro Sakaguchi Miyuki Takao Yasuo Ohyama Hiroshi Oka Hiroshi Yamashita Takumi Fukuchi Kiyoshi Ashida Masahiro Murotani Masuyo Murotani Kazuo Majima Hiroshi Morikawa Takashi Hashimoto Keisuke Kiyota Hirohiko Esaki Kanji Amemoto Gouhei Isowa Fumiyuki Takao | 2012 | World Journal of Gastroenterology2012，18，13： | 8 |
| 5 | Endoscopic naso-pancreatic drainage for the treatment of pancreatic fistula occurring after LDLT显示文摘Pancreatic fistula is a quite rare complication in patients who undergo living donor liver transplantation(LDLT).However,in the cases that show pancreatic fistula,the limited volume of the graft and the resultant inadequate liver function may complicate the management of the fistula.As a result,the pancreatic fistula may result in the death of the patient.We present 2 cases in whichendoscopic treatment was effective against pancreatic fistulas that developed after LDLT.In case 1,a 61-yearold woman underwent LDLT for primary biliary cirrhosis.Because of a portal venous thrombus caused by a splenorenal shunt,the patient underwent portal vein reconstruction,and a splenorenal shunt was ligated on postoperative day(POD)7.The main pancreatic duct was injured during the manipulation to achieve hemostasis,thereby necessitating open drainage.However,discharge of pancreatic fluid continued even after POD 300.Endoscopic naso-pancreatic drainage(ENPD)was performed,and this procedure resulted in a remarkable decrease in drain output.The refractory pancreatic fistula healed on day 40 after ENPD.In case 2,a 58-year-old man underwent LDLT for cirrhosis caused by the hepatitis C virus.When the portal vein was exposed during thrombectomy,the pancreatic head was injured,which led to the formation of a pancreatic fistula.Conservative therapy was ineffective;therefore,ENPD was performed.The pancreatic fistula healed on day 38 after ENPD.The findings in these 2 cases show that endoscopic drainage of the main pancreatic duct is a less invasive and effective treatment for pancreatic fistulas that develop after LDLT. | Akihisa Nagatsu Toshiya Kamiyama Satoru Todo Masahiko Taniguchi Tomomi Suzuki Hiroyuki Furukawa Tsuyoshi Shimamura Kenichiro Yamashita Hiroshi Kawakami Daisuke Abo | 2011 | World Journal of Gastroenterology2011，17，30： | 5 |
| 6 | Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study显示文摘AIM To assess the relationship between serum levels of insulin-like growth factor-1(IGF1)/IGF-binding protein-3(IGFBP3)and the risk of esophageal carcinoma.METHODS We assessed the relationship between the serum levels of these molecules and the risk of esophageal cancer in a prospective,nested case-control study of participants from the Japan Collaborative Cohort Study.A baseline survey was conducted from 1988 to 1990.Of the 110585 enrolled participants,35%donated blood samples.Those who had been diagnosed with esophageal cancer were considered cases for nested case-control studies.A conditional logistic model was used to estimate odds ratios for the incidence of esophageal cancer associated with serum IGF1 and IGFBP3 levels.RESULTS Thirty-one cases and 86 controls were eligible for the present assessment.The molar ratio of IGF1/IGFBP3,which represents the free and active form of IGF1,was not correlated with the risk of esophageal carcinoma.A higher molar difference between IGFBP3and IGF1,which estimates the free form of IGFBP3,was associated with a decreased risk of esophageal carcinoma(P=0.0146),and people in the highest tertile had the lowest risk(OR=0.107,95%CI:0.017-0.669).After adjustment for body mass index,tobacco use,and alcohol intake,the molar difference of IGFBP3-IGF1 was inversely correlated with the risk of esophageal carcinoma(P=0.0150).CONCLUSION The free form of IGFBP3,which is estimated by this molar difference,may be inversely associated with esophageal cancer incidence. | Yasushi Adachi Masanori Nojima Mitsuru Mori Kentaro Yamashita Hiro-o Yamano Hiroshi Nakase Takao Endo Kenji Wakai Kiyomi Sakata Akiko Tamakoshi | 2017 | World Journal of Gastroenterology2017，23，19： | 4 |
| 7 | Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse显示文摘背景雌激素受体 alpha (嗯一)是最重要的内分泌的治疗应答预言者因为有对内分泌的治疗的反应的预言的胸 cancer.The 精确性的女人被认为被包含雌激素受体 coregulatory 蛋白质和串音在之间影响嗯并且另外的生长发信号因素的 networks.Nuclear corepressor 1 ( NCOR1 )是学习客观的抄写 repressor.The 是在蛋白质 le 调查 NCOR1 | ZHANG Zhen-huan Hiroko Yamashita Tatsuya Toyama Yutaka Yamamoto Teru Kawasoe Mutsuko lbusuki Saori Tomita Hiroshi Sugiura Shunzo Kobayashi Yoshitaka Fujii Hirotaka Iwase | 2009 | Chinese Medical Journal2009，，15： | 4 |
| 8 | Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages显示文摘 | Noriyuki Ouchi Shinji Kihara Yukio Arita Makoto Nishida Akifumi Matsuyama Yoshihisa Okamoto Masato Ishigami Hiroshi Kuriyama Ken Kishida Hitoshi Nishizawa Kikuko Hotta Masahiro Muraguchi Yasukazu Ohmoto Shizuya Yamashita Tohru Funahashi Yuji Matsuzawa | 2001 | Circulation: Journal of the American Heart Association2001，，8： | 2 |
| 9 | Heparin bridge therapy and post-polypectomy bleeding显示文摘AIM To identify risk factors for post-polypectomy bleeding(PPB), focusing on antithrombotic agents. METHODS This was a case-control study based on medical records at a single center. PPB was defined as bleeding that occurred 6 h to 10 d after colonoscopic polypectomy and required endoscopic hemostasis. As risk factors for PPB, patient-related factors including anticoagulants, antiplatelets and heparin bridge therapy as well as polyp- and procedure-related factors were evaluated. All colonoscopic hot polypectomies, endoscopic mucosal resections and endoscopic submucosal dissections performed between January 2011 and December 2014 were reviewed. RESULTS PPB occurred in 29(3.7%) of 788 polypectomies performed during the study period. Antiplatelet or anticoagulant agents were prescribed for 210(26.6%)patients and were ceased before polypectomy except for aspirin and cilostazol in 19 cases. Bridging therapy using intravenous unfractionated heparin was adopted for 73 patients. The univariate analysis revealed that anticoagulants, heparin bridge, and anticoagulants plus heparin bridge were significantly associated with PPB(P < 0.0001) whereas antiplatelets and antiplatelets plus heparin were not. None of the other factors including age, gender, location, size, shape, number of resected polyps, prophylactic clipping and resection method were correlated with PPB. The multivariate analysis demonstrated that anticoagulants and anticoagulants plus heparin bridge therapy were significant risk factors for PPB(P < 0.0001). Of the 29 PPB cases, 4 required transfusions and none required surgery. A thromboembolic event occurred in a patient who took anticoagulant. CONCLUSION Patients taking anticoagulants have an increased risk of PPB, even if the anticoagulants are interrupted before polypectomy. Heparin-bridge therapy might be responsible for the increased PPB in patients taking anticoagulants. | Toshiyuki Kubo Kentaro Yamashita Kei Onodera Tomoya Iida Yoshiaki Arimura Masanori Nojima Hiroshi Nakase | 2016 | World Journal of Gastroenterology2016，22，45： | 2 |
| 10 | Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer显示文摘 | Yuji Ueda Hisakazu Yamagishi Daisuke Ichikawa Kazuma Okamoto Eigo Otsuji Jun Morii Kinya Koizumi Naoki Kakihara Masataka Shimotsuma Tetsuro Yamashita Fumihiro Taniguchi Hideki Aragane Hiroshi Nishi Yoshiki Itokawa Satoshi Morita Junichi Sakamoto | 2010 | Gastric Cancer2010，，3： | 2 |
| 11 | Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-κB Signaling Through a cAMP-Dependent Pathway显示文摘 | Noriyuki Ouchi Shinji Kihara Yukio Arita Yoshihisa Okamoto Kazuhisa Maeda Hiroshi Kuriyama Kikuko Hotta Makoto Nishida Masahiko Takahashi Masahiro Muraguchi Yasukazu Ohmoto Tadashi Nakamura Shizuya Yamashita Tohru Funahashi Yuji Matsuzawa | 2000 | Circulation: Journal of the American Heart Association2000，，11： | 2 |
| 12 | Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages显示文摘 | Noriyuki Ouchi Shinji Kihara Yukio Arita Makoto Nishida Akifumi Matsuyama Yoshihisa Okamoto Masato Ishigami Hiroshi Kuriyama Ken Kishida Hitoshi Nishizawa Kikuko Hotta Masahiro Muraguchi Yasukazu Ohmoto Shizuya Yamashita Tohru Funahashi Yuji Matsuzawa | 2001 | Circulation: Journal of the American Heart Association2001，，8： | 2 |
| 13 | Extended cancer-free survival after palliative chemoradiation for metastatic esophageal cancer显示文摘We report on a patient who remained cancer-free for an extended time after palliative radiotherapy(RT) and chemotherapy(nedaplatin plus 5-fluorouracil) treatment for stage Ⅳ(cT3N3M1) esophageal squamous cell carcinoma. Although multiple lymph nodes outside the RT field recurred, the local primary tumor within the RT field did not recur, even 17 mo after palliative RT of 30 Gy in 10 fractions. In this case, acute toxicity, such as myelosuppression or esophagitis, was not enhanced by increasing the fraction dose from 1.8-2.0 Gy to 3.0 Gy. Because 30 Gy in 10 fractions can be completed within a shorter time and is less expensive than 50.4 Gy in 28 fractions, we think that 30 Gy without oblique beams is a more favorable RT method for patients. | Hideomi Yamashita Kae Okuma Akihiro Nomoto Mami Yamashita Hiroshi Igaki Keiichi Nakagawa | 2014 | World Journal of Gastrointestinal Oncology2014，6，2： | 2 |
| 14 | Rapid detection of gene mutations responsible for non-syndromic aortic aneurysm and dissection using two different methods: resequencing microarray technology and next-generation sequencing显示文摘 | Haruya Sakai Shinichi Suzuki Takeshi Mizuguchi Kiyotaka Imoto Yuki Yamashita Hiroshi Doi Masakazu Kikuchi Yoshinori Tsurusaki Hirotomo Saitsu Noriko Miyake Munetaka Masuda Naomichi Matsumoto | 2012 | Human Genetics2012，，4： | 1 |
| 15 | Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy显示文摘 | HIROSHI YAMASHITA MATT J TYSKA DAVID M Warshaw | 2000 | J Biol Chem2000，275，28： | 1 |
| 16 | Development of API XI00 UOE line pipe显示文摘 | YOSHIO TERADA HIROSHI TAMEHIRO MITSUGU YAMASHITA | 1997 | Nippon Steel Technical Report1997，72，1： | 1 |
| 17 | Fast etching of silicon with a smooth surface in high temperature ranges near the boiling point of KOH solution显示文摘 | Tanaka Hiroshi Yamashita Shuichi Abe Yoshitsugu | 2004 | Sensors and Actuators A: Physical2004，114，23： | 1 |
| 18 | Novel Modulator for Endothelial Adhesion Molecules Adipocyte-Derived Plasma Protein Adiponectin显示文摘 | Noriyuki Ouchi Shinji Kihara Yukio Arita Kazuhisa Maeda Hiroshi Kuriyama Yoshihisa Okamoto Kikuko Hotta Makoto Nishida Masahiko Takahashi Tadashi Nakamura Shizuya Yamashita Tohru Funahashi Yuji Matsuzawa | 1999 | Circulation1999，，25： | 1 |
| 19 | 显示文摘 | Yamashita J Hiroshi I Hirashima M | 2000 | Nature2000，408，： | 1 |
| 20 | A globally and superlinearly convergent primal-dual interior point trust region method for large scale constrained optimization显示文摘 | Hiroshi Yamashita Hiroshi Yabe Takahito Tanabe | 2005 | Mathematical Programming2005，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员